2 terminated, 1 unknown. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Unknown 1 |
| Phase 2 | 3 | Terminated 2, Unknown 1 |
Follow AXT107: new trials by email Literature Review of AXT107 trials Research Report on AXT107
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose - Neovascular Age-related Macular Degeneration | Phase 1 / Phase 2 | Unknown | AsclepiX Therapeutics, Inc. | 15 | 2023-12-19 | 2024-05-06 |
| Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 1 / Phase 2 | Terminated | AsclepiX Therapeutics, Inc. | 3 | 2021-02-01 | 2024-03-22 |
| Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema AXT107 0.1 mg, AXT107 0.25 mg, AXT107 0.5 mg - Diabetic Macular Edema (DME) | Phase 1 / Phase 2 | Terminated | AsclepiX Therapeutics, Inc. | 6 | 2020-12-10 | 2024-03-22 |
Eye Diseases (2) · Retinal Diseases (2) · Diabetes Mellitus (1) · Diabetic Retinopathy (1) · Macular Degeneration (1) · Macular Edema (1) · Retinal Degeneration (1)
AsclepiX Therapeutics, Inc. (3)
United States (3)